|Publication number||USRE43187 E1|
|Application number||US 12/248,782|
|Publication date||Feb 14, 2012|
|Filing date||Oct 9, 2008|
|Priority date||Jan 13, 2003|
|Publication number||12248782, 248782, US RE43187 E1, US RE43187E1, US-E1-RE43187, USRE43187 E1, USRE43187E1|
|Inventors||Geoffrey A. Russell, W. Kenneth Ward, Ellen M. Anderson, Jonathan D. Birck|
|Original Assignee||Isense Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (22), Referenced by (13), Classifications (13), Legal Events (6)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation-in-part of application Ser. No. 10/342,144 filed Jan. 13, 2003 now U.S. Pat. No. 7,228,162.
Among the other unpleasant aspects of having the disorder diabetes mellitus is the need to frequently test one's blood glucose concentration. With current technology a diabetic patient must prick his own fingertip or other body part with a lancet in order to withdraw blood from the wound. The fingertip is preferred because of the great number of capillaries located there.
The breach created through the skin by the lancet must be wide enough to permit blood to flow through. Human epidermis around the fingertips is on the order of 1-3 millimeters thick. Also, similar to other flexible, sheet like materials, skin tends to close up on itself if breached. Accordingly the lancet used must create a breach that is wide enough to not be closed by the natural action of the skin.
Moreover, the task of sampling one's own blood has generally required that a flat surface be present for the patient to arrange various test articles including a test strip, a lancet and a cotton ball with alcohol, for sterilizing the wound. As a result, it has heretofore been impossible for a diabetic patient to measure his blood glucose level in a public place without drawing attention to himself. Interviews with diabetic patients indicate that the workplace, where there is frequently a definite lack of privacy and where maintaining the secrecy of personal information may be greatly desired, presents particular difficulties.
A number of disclosures are aimed at easing this requirement by providing an integrated unit having a number of lancets and associated test articles (such as a test strip or a sensing cavity to be filled with blood drawn out from the body) and in which both lancet and test article are contemporaneously moved into test position. These devices tend to use chemical test strips, rendering them rather bulky and typically requiring the user to place a test strip in place before use.
In addition, a number of disclosures are directed at an implantable or insertable sensor, for continuous glucose monitoring. Although this technology appears to bear promise it is desirable to have additional options for the diabetic patient. For example, a method of quickly and easily making an occasional determination of blood glucose concentration would be helpful for patients not wishing to wear a glucose monitor.
Ease of use is not only an important consideration from the perspective of patient comfort, but also from the perspective of patient health. The easier it is for a patient to take his blood glucose level reading, the more frequently he is likely to do so. In turn, with more frequent measurements, the patient is likely to do a better job at regulating his glucose level and thereby avoiding chronic complications in which body tissue is damaged by toxic glucose levels or acute complications in which the patient is in danger of entering a state of hypoglycemic shock. Moreover, by more frequently measuring his or her glucose levels, the patient will likely form a better understanding of his body's response to the consumption of varying types of food and of varying degrees of physical exertion. The better the patient understands his body's response characteristics the better he will be able to tailor his eating, exercise and insulin injection or ingestion regime.
In a first separate aspect, the present invention is a method of measuring an analyte concentration in body fluid. The method includes the use of an analyte measuring device that has an analyte sensing element with a sharpened distal end and further has an indicating electrode covered by an absorbent layer. Also, an electric power, data processing and display device is adapted to mate to and activate the analyte sensing element by applying electric power to it and adapted to receive the raw analyte measurement and to compute and display a refined analyte measurement from the raw analyte measurement. The analyte sensing element is introduced into the body of the subject, thereby placing the absorbent layer into contact with the body fluid. The absorbent layer becomes saturated with body fluid and the analyte sensing element is removed from the body and is activated to perform a raw analyte measurement which is used to calculate and display a refined analyte measurement.
In a second separate aspect, the present invention is an analyte sensing element adapted to be introduced into the body and removed from the body in a time period of less than about 2 seconds. The sensing element includes a rigid longitudinal body having a sharpened distal end to facilitate introduction into the body and an indicating electrode covered by an absorbent layer located on the rigid longitudinal body.
In a third separate aspect the present invention is a set of analyte sensing elements, each of which includes a rigid longitudinal body having a sharpened distal end to facilitate introduction into the body. In addition, each sensing element has an indicating electrode covered by an absorbent layer located on the rigid longitudinal body. All of the absorbent layers are adapted to absorb an equal amount of body fluids, to a tolerance of 10%.
In a fourth separate aspect, the present invention is an analyte measuring device that includes an analyte sensing element with a sharpened distal end to facilitate introduction into an animal body. The sensing element also has an indicating electrode covered by an absorbent layer. The device also includes an electric power, data processing and display assembly adapted to mate to the analyte sensing element and activate the analyte sensing element by applying electric power to it and adapted to receive the raw analyte measurement and to compute and display a refined analyte measurement, related to the raw analyte measurement.
In a fifth separate aspect, the present invention is an analyte sensing element, having an electrochemically active surface, sealingly covered by a layer that includes a conductive, redox mediating polymer. In one preferred embodiment, this polymer is in turn covered by an enzyme and enzyme cofactor layer. In an alternative preferred embodiment, the enzyme and enzyme cofactor are mixed into the layer that includes a conductive, redox mediating polymer.
In a sixth separate aspect the present invention is a method of making an analyte sensing element. First, a substrate having an electrochemically active surface is provided. Next, a sealing layer that includes a conductive, redox mediating polymer is formed onto said electrochemically active surface.
In a seventh separate aspect the present invention is an analyte sensing element comprising an electrochemically active surface and a layer comprised of a conductive, redox mediating polymer, sealingly applied to the electrochemically active surface. In addition, a layer that includes an enzyme and an enzyme cofactor mixed with absorbent material coats the conductive, redox mediating polymer.
The foregoing and other objectives, features and advantages of the invention will be more readily understood upon consideration of the following detailed description of the invention, taken in conjunction with the accompanying drawings.
Because sensing element 12 yields the sensing current during its brief indwell period, there is no need to withdraw blood front the body. As a result, sensing element 12 is thinner at its distal end (<300 micrometers thick) than lancets adapted to create a puncture through the skin that is sufficient to permit blood flow therethrough.
Needle 20 has a diameter of 227 microns and has a needle core 24 of structurally robust material such as stainless steel that is 226 microns thick and an electrochemically active plating 26, such as platinum, that is less than a micron thick. Alternative structurally robust materials that may be used for inner core 24 are tantalum, tungsten, stainless steel or nitinol. Although copper is forbidden in implants, as it is quite toxic, an inner core 24 of copper is possible in this application because needle 20 only briefly (typically <5 seconds) resides in the body.
In a preferred method of producing a thin platinum coating over stainless steel, a strike, or extremely thin (<1 nm) coating of gold is first electroplated onto the stainless steel core. Then, platinum is electroplated in a bath having a current density on the order of 40 amperes/ft2 or less. It is important to electroplate with a comparatively low current density, causing a slow buildup of platinum, in order to prevent uneven growth of the platinum layer.
Although as noted, needle 20 may be a core 24 with plating 26, other embodiments are also possible. For example, needle 20 may be made from a drawn filled tube that has been cut and sharpened or cut on a bias, to make it sharp, or which is naturally sharp, as it is very thin. In another alternative, needle 20 includes a core of structurally robust material that is covered with an outer layer 26 that is made of foil of electrochemically active material such as platinum. In alternative preferred embodiments outer layer 26 may be palladium or gold.
The membrane system 22 must perform a number of functions. First, it must provide an enzyme that reacts with glucose and oxygen to form peroxide or some other electrochemically active species. A reactive layer 30 of glucose oxidase, glutaraldehyde and albumin produces hydrogen peroxide when contacted by glucose and oxygen, performs this function.
Second, because glucose is far more prevalent in the blood and other body fluids than oxygen, system 22 must include a membrane placed over the reactive layer 30 to permit a greater permeation of oxygen than glucose, so that the glucose concentration measurement is not limited by the oxygen concentration in the immediately surrounding tissue. This function is performed by a permselective hard block/soft block copolymer layer 32. This layer is of the type described in U.S. Pat. Nos. 5,428,123; 5,589,563 and 5,756,632, which are hereby incorporated by reference as if fully set forth herein. Layer 32 is preferably less than 10 microns thick, to permit rapid permeation by glucose and oxygen.
Third, membrane system 22 must prevent interferents, such as acetaminophen, from corrupting the measurement by causing current flow unrelated to the presence of glucose. This function is performed by an inner interferent reducing layer 34 of a compound such as sulfonated polyether sulfone, polyamino-phenol, or polypyrrole, in one embodiment 3-amino-phenol, which quickly permits the permeation of the hydrogen peroxide, which causes the current flow indicative of the concentration of glucose. Persons skilled in the relevant arts will readily recognize that quick permeation is highly desirable in a briefly indwelling sensor so that a measurement may be quickly obtained.
To produce sensing element 12, first the interferent reducing layer 34 of 3-amino-phenol is solution-coated or electro polymerized onto the surface of platinum plating 26. Layer 34 may be from a few nanometers to 2 microns thick, to permit rapid permeation by H2O2 ions, thereby reacting very quickly to glucose concentration. Over this the reactive layer 30 of glucose oxidase is dip-coated or electrodeposited. Glutaraldehyde is deposited on the glucose oxidase to immobilize the glucose oxidase. The sensor is dip coated in the soft block/hard block copolymer 32. In the finished product, the surface of the sensing region 22 is slightly depressed relative the remainder of the surface of sensing element 12. In one embodiment, the glucose oxidase 30 is applied before layer 34, which is electrodeposited through layer 30.
Layer 132 is a layer of absorbent material such as carboxymethylcellulose, gelatin, or a microporous coating composed of inorganic particles in a polymeric binder. This permits element 112 to be briefly introduced into human flesh and then withdrawn with the absorbent material 132 saturated with body fluids. Not only does this permit a brief period of sensor indwelling, but also assures a sample having a predetermined volume. Because spreading layer 132 assures a complete wetting of layer 130, elements 172 may serve as a reference electrode assembly.
For sensing assembly 10, in one embodiment, a case 52 of the durable portion 16 serves as a reference electrode. The user grasps the case 52 in his right hand (left hand if the patient is left handed) and pushes a sensing element 12 into either his left arm or a left hand fingertip. When sensing element 12 enters the user's flesh, the circuit is completed through the user's body. Other reference electrode structures can consist of the portion of the housing immediately surrounding the indicating electrode or a patch placed upon the skin.
In one preferred embodiment the sensing element 12 is energized to a preset bias voltage level, which may be at a level of from 0.2 VDC to 0.8 VDC between cathode and anode, contemporaneously with being introduced into the patient. (We are currently examining whether there are advantages to using a lower bias voltage to eliminate some of the interferents.) In one embodiment a pair of contacts 72 positioned at the top of the sensing region 22 is electrically connected by body fluid when the sensing region 22 is entirely covered by body fluid. This is used to trigger the application of voltage to the sensing element 12.
After insertion the patient waits for approximately six seconds at which time the controls and display unit 18 provides a reading of the blood glucose level. After this, unit 64 pulls sensing element 12 back into magazine 60, where it is stored until all of magazine 60 is detached from the durable portion 16 and placed in a proper disposal receptacle. Subsequently, a new magazine 60 is attached into durable portion 16, for further measurements. To support this option, in a preferred method, new magazines 60, filled with sensors 12 are made and sold. Alternatively, the entire assembly 10 is disposable and comes as a single non-separable unit.
Accordingly, in one preferred embodiment the direction of change, after correction for the initial transient current, is computed and displayed. In another embodiment a weighted average is formed of the corrected measurements, with more recent measurements being weighted more heavily, to give the patient a reading that reflects more heavily the more recent measurements. In yet another preferred embodiment, the processor simply waits until the initial transient current has dissipated, and then computes an instantaneous or brief period glucose concentration at the latest possible moment, in order to provide the patient with the timeliest information.
In an additional preferred embodiment, the signal processing unit 17 time tags and stores each glucose concentration estimate and uses this stream of time tagged estimates to send a value representing glucose concentration change to the controls and display unit 18.
The terms and expressions which have been employed in the foregoing specification are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding equivalents of the features shown and described or portions thereof, it being recognized that the scope of the invention is defined and limited only by the claims which follow.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3662745 *||Jun 30, 1969||May 16, 1972||Hoffmann La Roche||Metal-metal salt electrode and method for making the same|
|US4671288||Jun 13, 1985||Jun 9, 1987||The Regents Of The University Of California||Electrochemical cell sensor for continuous short-term use in tissues and blood|
|US4711245||May 7, 1984||Dec 8, 1987||Genetics International, Inc.||Sensor for components of a liquid mixture|
|US4953552 *||Apr 21, 1989||Sep 4, 1990||Demarzo Arthur P||Blood glucose monitoring system|
|US5181995||Oct 1, 1990||Jan 26, 1993||Ford Motor Company||Electrochemical process and apparatus for reducing oxidants of vehicle interior air|
|US5510266||May 5, 1995||Apr 23, 1996||Bayer Corporation||Method and apparatus of handling multiple sensors in a glucose monitoring instrument system|
|US5711861 *||Nov 22, 1995||Jan 27, 1998||Ward; W. Kenneth||Device for monitoring changes in analyte concentration|
|US5820622||Dec 18, 1996||Oct 13, 1998||Elan Medical Technologies Limited||Analyte-controlled liquid delivery device and analyte monitor|
|US5871494||Dec 4, 1997||Feb 16, 1999||Hewlett-Packard Company||Reproducible lancing for sampling blood|
|US6083710 *||Jun 16, 1999||Jul 4, 2000||E. Heller & Company||Electrochemical analyte measurement system|
|US6193873||Jun 15, 1999||Feb 27, 2001||Lifescan, Inc.||Sample detection to initiate timing of an electrochemical assay|
|US6352514||Apr 19, 2000||Mar 5, 2002||Amira Medical||Methods and apparatus for sampling and analyzing body fluid|
|US6375627 *||Mar 2, 2000||Apr 23, 2002||Agilent Technologies, Inc.||Physiological fluid extraction with rapid analysis|
|US6561989||Jun 11, 2001||May 13, 2003||Bayer Healthcare, Llc||Thin lance and test sensor having same|
|US6612111 *||Mar 27, 2000||Sep 2, 2003||Lifescan, Inc.||Method and device for sampling and analyzing interstitial fluid and whole blood samples|
|US6706159||Mar 2, 2000||Mar 16, 2004||Diabetes Diagnostics||Combined lancet and electrochemical analyte-testing apparatus|
|US6793632||Jun 12, 2001||Sep 21, 2004||Lifescan, Inc.||Percutaneous biological fluid constituent sampling and measurement devices and methods|
|US20020004196 *||Jun 11, 2001||Jan 10, 2002||Bayer Corporation||Thin lance and test sensor having same|
|US20020168290 *||May 9, 2002||Nov 14, 2002||Yuzhakov Vadim V.||Physiological sample collection devices and methods of using the same|
|US20020188221 *||Jun 12, 2001||Dec 12, 2002||Borzu Sohrab||Percutaneous biological fluid constituent sampling and measurement devices and methods|
|US20030217918||Mar 21, 2003||Nov 27, 2003||Davies Oliver William Hardwicke||Rapid response glucose sensor|
|US20030223906||Jun 3, 2002||Dec 4, 2003||Mcallister Devin||Test strip container system|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8583204||Mar 5, 2010||Nov 12, 2013||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US8682408||Mar 5, 2010||Mar 25, 2014||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US8954128||Oct 18, 2013||Feb 10, 2015||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US9173606||Jan 30, 2014||Nov 3, 2015||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US9173607||Jan 30, 2014||Nov 3, 2015||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US9549699||Oct 17, 2014||Jan 24, 2017||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US9566026||Oct 17, 2014||Feb 14, 2017||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US9572523||Sep 22, 2015||Feb 21, 2017||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US9693721||Jun 17, 2015||Jul 4, 2017||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US20090247855 *||Mar 27, 2009||Oct 1, 2009||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US20090247856 *||Mar 27, 2009||Oct 1, 2009||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US20100096259 *||Nov 30, 2009||Apr 22, 2010||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|US20100280341 *||Mar 5, 2010||Nov 4, 2010||Dexcom, Inc.||Polymer membranes for continuous analyte sensors|
|U.S. Classification||600/345, 600/347, 600/365|
|International Classification||A61B5/00, A61B5/05|
|Cooperative Classification||A61B5/6848, A61B5/14865, A61B5/1411, A61B5/150022, A61B5/150358|
|European Classification||A61B5/68D1B, A61B5/1486B, A61B5/14B2|
|May 23, 2014||REMI||Maintenance fee reminder mailed|
|Oct 10, 2014||LAPS||Lapse for failure to pay maintenance fees|
|Oct 10, 2014||REIN||Reinstatement after maintenance fee payment confirmed|
|Jan 18, 2017||AS||Assignment|
Owner name: WAVEFORM TECHNOLOGIES, INC., NEW HAMPSHIRE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AGAMATRIX, INC.;REEL/FRAME:041394/0955
Effective date: 20170113
|Jan 27, 2017||AS||Assignment|
Owner name: MIDCAP FINANCIAL TRUST, AS AGENT, MARYLAND
Free format text: SECURITY INTEREST;ASSIGNOR:WAVEFORM TECHNOLOGIES, INC.;REEL/FRAME:041517/0950
Effective date: 20170125
|Sep 29, 2017||AS||Assignment|
Owner name: WAVEFORM TECHNOLOGIES, NEW HAMPSHIRE
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FINANCIAL TRUST;REEL/FRAME:043745/0347
Effective date: 20170929